Patel S, Thompson W, Sivaswamy A, Khan A, Ferreira-Legere L, Lee DS, Abdel-Qadir H, Jackevicius C, Goodman S, Farkouh ME, Tu K, Kapral MK, Wijeysundera HC, Tam D, Austin PC, Fang J, Ko DT, Udell JA. Development and validation of a model to categorize cardiovascular cause of death using health administrative data. AHJ Plus. 2022 Oct;22:100207. doi: 10.1016/j.ahjo.2022.100207
Chambers TM, Agopian AJ, Lewis RA, Langlois PH, Danysh HE, Weber KA, Shaw GM, Mitchell LE, Lupo PJ. Epidemiology of anophthalmia and microphthalmia: prevalence and patterns in Texas, 1999-2009. Am J Med Genet A. 2018 Sep;176(9):1810-8. doi: 10.1002/ajmg.a.40352
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Wheeler A, Raspa M, Bann C, Bishop E, Hessl D, Sacco P, Bailey DBJr. Anxiety, attention problems, hyperactivity, and the aberrant behavior checklist in fragile x syndrome. Am J Med Genet A. 2014 Jan;164A(1):141-55. doi: 10.1002/ajmg.a.36232
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.